Suchen
Maze Therapeutics Inc
MAZEZur Watchlist hinzufügen
24.580USD
-1.790-6.79%
Handelsschluss 09-09 16:00（ET）
1.37BMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Maze Therapeutics Inc Unternehmen
Maze Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in harnessing the power of human genetics and variant functionalization with its Maze Compass platform to develop small-molecule precision medicines for the treatment of renal, cardiovascular and related metabolic diseases, including obesity. The Compass platform has been purpose-built to inform all phases of drug discovery and development process through clinical trial design, advancing two wholly owned lead programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach to chronic kidney disease (CKD). Its lead program, MZE829, is an oral, small-molecule inhibitor of apolipoprotein L1, or APOL1, for the treatment of patients with APOL1 kidney disease, or AKD. Its second lead program, MZE782, is an oral, small-molecule inhibitor of the solute transporter SLC6A19, a novel CKD target.
Maze Therapeutics Inc Profil
BörsenkürzelMAZE
Name des UnternehmensMaze Therapeutics Inc
IPO-datumJan 31, 2025
CEOColoma (Jason V)
Anzahl der mitarbeiter125
WertpapierartOrdinary Share
GeschäftsjahresendeJan 31
Addresse171 Oyster Point Boulevard, Suite 300
StadtSOUTH SAN FRANCISCO
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl94080
Telefon16508505070
Websitehttps://www.mazetx.com/
BörsenkürzelMAZE
IPO-datumJan 31, 2025
CEOColoma (Jason V)
Führungskräfte von Maze Therapeutics Inc
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Jonathan E. Lim, M.D.
Dr. Jonathan E. Lim, M.D.
Independent Director
Independent Director
328.70K
--
Dr. Sekar (Sek) Kathiresan, M.D.
Dr. Sekar (Sek) Kathiresan, M.D.
Independent Director
Independent Director
103.72K
--
Mr. Atul Dandekar
Mr. Atul Dandekar
Chief Strategy and Business Officer
Chief Strategy and Business Officer
35.75K
+34.97%
Dr. Harold Bernstein, M.D., Ph.D.
Dr. Harold Bernstein, M.D., Ph.D.
President - Research and Development, Chief Medical Officer
President - Research and Development, Chief Medical Officer
20.00K
--
Ms. Amy Bachrodt
Ms. Amy Bachrodt
Investor Contact
Investor Contact
12.96K
--
Dr. Charles Homcy, M.D.
Dr. Charles Homcy, M.D.
Co-Founder, Director
Co-Founder, Director
--
--
Dr. Jason V. Coloma, Ph.D.
Dr. Jason V. Coloma, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Ms. Courtney J. Phillips
Ms. Courtney J. Phillips
General Counsel, Corporate Secretary
General Counsel, Corporate Secretary
--
--
Dr. Nancy C. Andrews, M.D., Ph.D.
Dr. Nancy C. Andrews, M.D., Ph.D.
Independent Director
Independent Director
--
--
Dr. Jamie Brush, M.D.
Dr. Jamie Brush, M.D.
Independent Director
Independent Director
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Jonathan E. Lim, M.D.
Dr. Jonathan E. Lim, M.D.
Independent Director
Independent Director
328.70K
--
Dr. Sekar (Sek) Kathiresan, M.D.
Dr. Sekar (Sek) Kathiresan, M.D.
Independent Director
Independent Director
103.72K
--
Mr. Atul Dandekar
Mr. Atul Dandekar
Chief Strategy and Business Officer
Chief Strategy and Business Officer
35.75K
+34.97%
Dr. Harold Bernstein, M.D., Ph.D.
Dr. Harold Bernstein, M.D., Ph.D.
President - Research and Development, Chief Medical Officer
President - Research and Development, Chief Medical Officer
20.00K
--
Ms. Amy Bachrodt
Ms. Amy Bachrodt
Investor Contact
Investor Contact
12.96K
--
Dr. Charles Homcy, M.D.
Dr. Charles Homcy, M.D.
Co-Founder, Director
Co-Founder, Director
--
--
Häufig gestellte Fragen
Wer sind die fünf größten Anteilseigner von Maze Therapeutics Inc?
Die fünf größten Anteilseigner von Maze Therapeutics Inc sind: Dr. Jonathan E. Lim, M.D.
Wie viele Institutionen halten Anteile an Maze Therapeutics Inc (MAZE)?
Mit Stand vom 2026Q1 halten 213 Institutionen Anteile an Maze Therapeutics Inc, mit einem Gesamtmarktwert von etwa 53.41M, was 97.33% der Gesamtanteile entspricht. Im Vergleich zum 2025Q4 ist der institutionelle Aktienbesitz um 12392855.00 gestiegen.